A Systematic Review of Meta-Analyses that Evaluate Risk Factors for Dementia to Evaluate the Quantity, Quality, and Global Representativeness of Evidence

Kaarin J. Anstey\textsuperscript{a,b,*}, Nicole Ee\textsuperscript{a,b}, Ranmalee Eramudugolla\textsuperscript{b}, Carol Jagger\textsuperscript{c} and Ruth Peters\textsuperscript{a,b}

\textsuperscript{a}School of Psychology, University of New South Wales, Sydney, NSW, Australia
\textsuperscript{b}Neuroscience Research Australia (NeuRA), Sydney, NSW, Australia
\textsuperscript{c}Newcastle Institute for Ageing, Newcastle University, Newcastle, UK

Accepted 20 May 2019

Abstract.

Background: The translation of evidence on dementia risk factors into clinical advice requires careful evaluation of the methodology and scope of data from which risk estimates are obtained.

Objective: To evaluate the quantity, quality, and representativeness of evidence, we conducted a review of reviews of risk factors for Alzheimer’s disease (AD), Vascular dementia (VaD), and Any Dementia.

Methods: PubMed, Cochrane library, and the Global Index Medicus were searched to identify meta-analyses of observational studies of risk factors for AD, VaD, and Any Dementia. PROSPERO CRD42017053920.

Results: Meta-analysis data were available for 34 risk factors for AD, 26 risk factors for Any Dementia and eight for VaD. Quality of evidence varied greatly in terms of the number of contributing studies, whether data on midlife exposure was available, and consistency of measures. The most evidence was available for cardiovascular risk factors. The most geographically representative evidence (five of six global regions) was available for alcohol, physical activity, diabetes, high midlife BMI, antihypertensives, and motor function. Evidence from Australia/Oceana or Africa was limited. With the exception of diabetes, meta-analysis data were unavailable from Latin America/Caribbean. Midlife specific data were only available for cholesterol and arthritis.

Conclusion: There is a lack of midlife specific data, limited data on VaD, and a lack of geographical representation for many risk factors for dementia. The quality, quantity, and representativeness of evidence needs to be considered before recommendations are made about the relevance of risk factors in mid- or late-life or for dementia subtypes.

Keywords: Alzheimer’s disease, cohort studies, meta-analysis, prevention, risk factor, vascular dementia

INTRODUCTION

Dementia prevalence will continue to increase due to population aging and will cause a significant burden of disease [1], unless the onset of dementia is delayed [2]. Older adults commonly have dementia of mixed pathology that is amenable to modification by treatment of vascular risk factors. Therefore, data on risk factors for dementia is increasingly used to inform national preventative health policy as illustrated by the recent publication of evidence reports [3, 4]. However, the evidence base to support recommendations for dementia risk reduction falls short of what is a growing demand by the
scientific community for reproducibility of methods and results. The 2017 Lancet Commission report [4] made recommendations for risk reduction based on two sources: a United States Government Report published in 2010 [5]; and the United Kingdom National Clinical Practice Guidelines (NICE guidelines) [6], which provided a narrative review of the literature. It concluded that childhood education, exercise, maintaining social engagement, reducing smoking, and management of hearing loss, depression, diabetes, and obesity are key risk factors which collectively have the potential to delay or prevent a third of dementia cases [4]. The recent United States National Academies’ Consensus Report focused on systematic reviews of interventions, and identified cognitive training, hyper/hypotension and physical activity as reducing dementia risk but that evidence for these was only modest [3]. There has been limited quantitative evaluation of the volume, quality, and generalizability of the body of observational evidence available for putative risk factors for dementia. Global recommendations have been based on findings drawn from narrow geographical regions and with limited age range. Evaluating the breadth and depth of a body of evidence allows for clarification of evidence gaps, areas of bias, and provides a bird’s eye view of the field [7]. We therefore aimed to conduct a novel umbrella systematic review of the observational evidence for risk factors for dementia to produce an overview of the global evidence in the field, focusing on the types of information required to underpin the development of clinical practice guidelines [8]. We evaluate both the quantity of evidence and its representativeness, and identify areas of bias resulting from pooling of results in meta-analyses.

MATERIALS AND METHODS

Search strategy and eligibility criteria

A systematic review of reviews was conducted [9], and pre-registered in PROSPERO CRD42017053920. PubMed, the Cochrane Library, and the Global Index Medicus (which covered LILACS, WPRIM, IMEMR, IMSEAR, WHO IRIS, AIM, MedCarib) (inception to 8, September 2018) and reference lists of retrieved articles were also manually searched and content experts in the field were consulted for other relevant publications.

The following search strategies were employed: PubMed/Medline: (risk OR “protective factors” OR ((prevention and control[MeSH Terms]) OR risk factors[MeSH Terms]) OR etiology[MeSH Terms]) OR epidemiology[MeSH Terms]) AND dementia OR alzheimer’s OR alzheimers OR alzheimer OR “dementia”[Mesh] OR “cognitive dysfunction”[Mesh] OR healthy brain OR brain health) AND (meta-analysis OR meta-analyses) AND systematic[sb]; Cochrane Library: #1: MeSH descriptor: [Dementia] explode all trees; #2: MeSH descriptor: [Mild Cognitive Impairment] explode all trees; #3: MeSH descriptor: [Causality] explode all trees; #4: MeSH descriptor: [Epidemiologic Factors] explode all trees; #5: #1 or #2; #6: #3 or #4; #7: #5 and #6 in Other Reviews; Global Index Medicus: mh:(“Alzheimer Disease” OR “Dementia, Vascular” OR “Dementia”) AND (mh:(“Risk Factors” OR “Causality” OR “Epidemiologic Factors; PycINFO:

1 exp Protective Factors/ (4806)
2 exp Etiology/ or exp Risk Factors/ or exp Epidemiology/ (142956)
3 exp PREVENTION/ (55681)
4 cognitive dysfunction.mp. (5918)
5 alzheimer’s disease.mp. or exp Alzheimer’s Disease/ (55884)
6 exp DEMENTIA/ or DEMENTIA.mp. (90379)
7 risk.mp. (346369)
8 (meta-analysis or meta-analyses).mp. [mp = title, abstract, heading word, table of contents, key concepts, original title, tests & measures] (30891)
9 1 or 2 or 3 or 7 (438985)
10 4 or 5 or 6 (101538)
11 8 and 9 and 10 (618)
12 limit 11 to “0830 systematic review” (121)
13 limit 12 to yr = “1860 - 2018” (120)

Any systematic review of a risk factor for Alzheimer’s disease (AD), Vascular dementia (VaD), or Any Dementia was eligible. Reviews were excluded if they specified their primary outcome was early-onset dementia/familial AD. Only reviews of longitudinal studies were included. If a pooled estimate contained cross-sectional and longitudinal data, hazard ratios for longitudinal primary studies were extracted and risk ratios re-pooled. Reviews were excluded if the majority of primary studies obtained dementia diagnoses from medical records solely, if they included primarily clinical samples, did not report inclusion and exclusion criteria, did not conduct meta-analyses, or were not published in peer-reviewed journals, so as to exclude low quality
reviews. Non-English publications were translated with Google Translate.

**Data screening and extraction**

Citations of all publications returned by the search strategies were screened for duplicates and remaining reviews screened in two further stages. At least two independent reviewers rated each article; inconsistencies in decisions on inclusion were resolved through discussion and consensus. Abstracts were screened for relevance and where there was insufficient information available for a decision, they were tentatively included. All remaining publications underwent full-text review for assessment against inclusion and exclusion criteria.

Data extracted for potential meta-analysis and narrative review included: risk exposure measured at midlife (<65 years) or late-life (65+ years); dementia outcome (AD, VaD [10], and Any Dementia which, potentially included AD, VaD, dementia with Lewy bodies, frontotemporal dementia/Pick’s disease, alcohol related dementia, mixed and other dementias); study design (sample source, number of participants, observation period), sample characteristics (country, percentage female, average age of participants included in the review, age range, average years of education), risk factor reviewed, number of studies, measurement of dementia or cognition, unadjusted and adjusted estimates of association, hazard ratio (HR), relative risk (RR), beta, \( p \)-values with 95% confidence intervals (CI), and \( I^2 \). From each article, we extracted the number of individual studies included in each meta-analysis, and the specific study details to allow for evaluation of how many studies were included in multiple meta-analyses, as well as the continent/region in which the original data were collected (North America, Europe, Asia/Middle East, Australia/Oceana, Africa, Latin America).

**Quality assessment**

The quality of evidence was evaluated at three levels: risk factor, meta-analysis (i.e., per pooled risk estimate), and publication and was informed by the literature on factors that affect the quality of evidence as identified by the GRADE initiative [11] and tailored specifically to dementia epidemiology. For example, AD pathology accumulates over decades and the prodromal period may last several years so that the significance of the length of exposure to a risk factor must be interpreted taking this into account.

**Risk factor evidence quality**

‘Body of Evidence Metrics (BEM)’ (Table 1) were developed based on the premise that a strong body of evidence for supporting dementia prevention programs across the world would draw from study populations that represent a wide range of countries and ethnicities, and include: mid- and late-life risk factors; information on the relationship of the risk factor to AD, VaD, and Any Dementia; high quality systematic reviews of sufficient sample size and length of follow-up, with consistently defined exposure and outcome measures. Ideally, the body of evidence would be based on recent studies, particularly for a risk factor that may be susceptible to history and cohort effects.

**Quantity and recentness of evidence**

1. Quantity of primary studies: The number of primary studies included per meta-analyses (n) (Table 1), the total number of unique primary studies per risk factor (N), and degree of overlap in inclusion of studies within individual meta-analyses (\( R = n/N \)) (Supplementary Table 1) were recorded.

2. Recency of reviews was calculated as the percentage of reviews published within the last five years (since 2013) for a given risk factor.

**Exposure**

3. Quality of exposure measure (Table 1): Use of standard definitions and variability of measures used for each risk factor and commentary on type of measure (e.g., categorical, scale). This metric evaluates variation in the consistency of exposure measures that are pooled in meta-analyses.

**Outcome**

4. Outcome measure as clinical diagnosis: the percentage of reviews that did or did not use a standard clinical outcome measure (i.e., Diagnostic and Statistical Manual, the International Classification of Diseases, and other widely used classification systems or Consensus criteria published by groups of experts).

5. Subtypes of dementia represented (AD, VaD, Any Dementia).

**Population**

6. Primary baseline age-group represented per risk factor (midlife 40–59; late-life 60+; and percentage of studies in which baseline age is unknown) [4].

7. Range of follow-up (Table 1) and percentage long-term follow-up: For each risk factor, the
| Risk Factor         | Exposure | N$^1$ | SR | Standardised measures | Comments               | Outcome | Population | Geographical regions$^4$ |
|---------------------|----------|-------|----|------------------------|------------------------|---------|------------|-------------------------|
| Education           |          |       |    |                        |                        |         |            |                         |
| Demographic         | Education| 36    | Y  | Categorical measures   | 100 - -                | AD      | adj -      | 1-37; ?                 |
|                     |          |       |    |                        |                        |         |            |                         |
| Bilingualism        |          | 3     |    |                        | Any Dementia           | adj -   | 2-30; ?    |                         |
| Alcohol             |          | 1     | 4  | Y Categorical measures | - 100 -                | Any Dementia | LL 75 | 5-23 | North America | Europe | Asia/Middle East | Australia/Oceania | Africa | Latin America/Caribbean |
|                     | Alcohol  | 4     | 25 | Categorical measures   | 50 - 50                | AD      | LL 38     | 2-10 | | | | |
|                     |          |       |    |                        | Any Dementia           | LL      | ML+LL 20 | 1-25 | | | | |
|                     |          |       |    |                        | VaD                    | LL      | - 2-7     | 2-7; ? | | | | |
| Cognitive engagement|          | 2     | 8  | N Varied measures,     | 100 - -                | AD      | LL 33     | 4-12 | | | | |
|                     |          |       |    | unclear definitions    |                        |         |            |             |
|                     |          |       |    |                        | Any Dementia           | LL 60   | 3.5-12    | | | | | |
| Diet                |          | 1     | 90 | N Varied subcategories,| 54 18 28               | AD      | ML+LL 34  | 2.1-29; ? | North America | Europe | Asia/Middle East | Australia/Oceania | Africa | Latin America/Caribbean |
|                     |          |       |    | unclear classification |                        |         |            |             |
|                     |          |       |    |                        | Any Dementia           | ML+LL   | 18 1.5-31.5; ? | | | | | |
| Physical activity   |          | 8     | 38 | Y Categorical measures | 100 - -                | AD      | ML+LL 21  | 3.9-21 | | | | | |

$^1$ N: Number of studies
$^2$ SR: Number of subjects
$^3$ Yes (%): Percentage of studies with a positive finding
$^4$ Age group: Age range for the studies
$^5$ % unknown: Percentage of studies with unknown data
$^6$ Range of follow-up (y): Follow-up period range of the studies

Table 1: Body of Evidence Metrics: Representativeness, quality and quantity of evidence per risk factor
|                      | Any Dementia | ML+LL | LL | - | 1-31 | 4-7.3 |
|----------------------|--------------|-------|----|---|------|-------|
| Sleep                |              |       |    |   |      |       |
| Clinical sleeping disorders/ shorter sleep duration | 33 67 - AD | ML+LL | LL | - | 2.3-12.5 |
| Smoking              | 6 45 Y       |       |    |   | 2.4-26 |
| Categorical measures | 17 33 50 AD  | ML+LL | LL | - | 2.47; ? |
| Social engagement    | 1 12 N       |       |    |   | 2-47 |
| Varied measures, 5 sub-constructs | - 100 - Any Dementia | ML+LL | LL | - | 2.9-15 |
| Stress               | 1 3 N        |       |    |   | 2-47 |
| Classification unclear, self-reported | 100 - AD | ML | 50 | 6 |
| Arthritis            | 2 5 Y        |       |    |   | 5-7.8 |
| Clinical criteria/diagnosis | 100 - AD | ML | 50 | 5 |
| Atrial fibrillation  | 4 17 Y       |       |    |   | 1-30; ? |
| Established clinical classification | 75 25 AD | LL | 9 | 1-30; ? |
| Anxiety              | 1 6 Y        |       |    |   | 2.3-4 |
| Clinical diagnosis/criteria | - 100 - Any Dementia | LL | 17 | 2.3-4 |
| BMI                  | 6 28 Y       |       |    |   | 3-36 |
| Categorical measures | 17 83 AD | ML+LL | LL | 19 | 3.2-40 |
| Cancer               | 2 7 Y        |       |    |   | 3.2-36 |
| Clinical criteria/diagnosis | 50 50 AD | ML+LL | LL | 18 | 3.7-22 |
| Carotid atherosclerosis | 1 2 Y | Clinical criteria/diagnosis | 100 - AD | LL | 7.9 |
| Cholesterol          | 5 21 Y       |       |    |   | 2.1-32; ? |
| Clinically thresholds of elevated cholesterol, validated measures | 80 20 AD | ML+LL | LL | 16 | 2.1-32; ? |
| Domain         | Exposure | SR | N¹ | Standardised measures | Yes (%) | No (%) | Unclear (%) | Specified clinical criteria³ | Subtypes⁴ | Ages⁵ | Range of follow-up (y) | Geographical regions⁶ |
|----------------|----------|----|----|-----------------------|---------|--------|-------------|-----------------------------|-----------|-------|-----------------------|------------------------|
| Depression     | 3        | 46 | Y  | Validated scales      | 6       | -      | 33          | AD                          | LL        | 51    | 2.5-30                | North America          |
|                |          |    |    | categorical/         | 7       |  7     |             |                             |           |       |                       | Europe                 |
|                |          |    |    | continuous measures  |         |        |             | Any Dementia                | LL        | 60    | 3-8                   | Asia/Middle East       |
|                |          |    |    |                        |         |        |             | VaD                         | LL        | 63    | 3.8-9                 | Australia/Oceania      |
| Diabetes       | 8        | 54 | Y  | Clinical diagnosis/  | 3       | 8      | -           | AD                          | ML+LL     | 37    | 2.25-1.7             | Africa                 |
|                |          |    |    | criteria              | 7       |        |             |                             |           |       |                       | Latin America/Caribbean|
| Hearing loss   | 1        | 13 | Y  | Clinical diagnosis/  | -       | 100    | -           | Any Dementia                | ML+LL     | 43    | 2.16.8                |                       |
|                |          |    |    | criteria              |         |        |             |                              |           |       |                       |                       |
| Homocysteine   | 3        | 11 | Y  | Established clinical | 6       | 7      | -           | AD                          | ML+LL     | 55    | 2.4-35                |                       |
|                |          |    |    | thresholds            | 7       |        |             |                              |           |       |                       |                       |
| Hormones      | 5        | 18 | N  | Varied hormones and  | 3       | 3      | -           | AD                          | LL        | 37    | 2.19.1                |                       |
|                |          |    |    | inconsistent measures |         |        |             |                              |           |       |                       |                       |
| Hyper/hypotension | 1      | 38 | Y  | Established clinical | 8       | 0      | -           | AD                          | ML+LL     | 19    | 1-32                  |                       |
|                |          |    |    | thresholds/ measures  | 0       |        |             |                              |           |       |                       |                       |
|                |          |    |    |                        |         |        |             | VaD                         | ML+LL     | 17    | 3.2-10                |                       |
| Factor                        | Category | Y/N | Measure                                      | Score | Estimate | 95% CI |
|-------------------------------|----------|-----|----------------------------------------------|-------|----------|--------|
| Inflammatory markers         |          | Y   | Established biomarkers                       | 100   | LL       | 6-25   |
| Metabolic syndrome           |          | Y   | Established clinical thresholds/ measures    | 100   | LL       | 4.25   |
| Motor function               |          | N   | Varied measures                              | 100   | LL       | 3.8-13.6 |
| Peripheral artery disease    |          | Y   | Established clinical thresholds/ measures    | 100   | LL       | 5-5.4  |
| Renal disease                |          | Y   | Established clinical thresholds/ measures    | 100   | LL       | 6-7.5  |
| Serum uric acid              |          | N   | Established clinical thresholds/ measures    | -100  | LL       | 3-11.1 |
| Stroke                       |          | Y   | Clinical diagnosis                           | 100   | LL       | 3-9    |
| TBI                          |          | Y   | Established clinical thresholds/ measures    | 33    | 67       | 1.2-14.5 |
| Antacids                     |          | Y   | Established drug class                       | 100   | ?        | 5-20   |
| Antihypertensives            |          | Y   | Established drug class                       | 33    | 33       | 2.2-32 |
| Anti-inflammatory            |          | Y   | Established drug class                       | 100   | ?        | <1-30  |
| Benzodiazepines              |          | Y   | Established drug class                       | 100   | ?        | 100    |

(Continued)
### Table 1 (Continued)

| Domain        | Risk Factor          | Exposure | SR | N | Standardised measures | Comments | Yes (%) | No (%) | Unclear (%) | Subtypes | Age group | % unknown | Range of follow-up (y) | Geographical regions |
|---------------|----------------------|----------|----|---|------------------------|----------|---------|--------|-------------|----------|-----------|-----------|------------------------|----------------------|
| Environmental | HRT                  | 3        | 9  | Y | Established drug class |          | 33      | 33     | 33          | AD       | LL        | 25        | 1-19.1                | Europe               |
|               | Insulin sensitisers  | 1        | 6  | Y | Established drug class |          | -       | -      | 100         | AD       | ?         | 100       | 10-11                  | Europe               |
|               |                      |          |    |   |                        |          |         |        |             | Any Dementia | ?         | 100       | 3.1-11                | Europe               |
|               | Statins              | 5        | 22 | Y | Established drug class |          | 50      | -      | 50          | AD       | ML+LL     | 69        | 3-12                  | Europe               |
|               |                      |          |    |   |                        |          |         |        |             | Any Dementia | ML+LL     | 62        | 3-24.9                | Europe               |
|               | Pesticides           | 2        | 3  | N | Unclear exposure levels/|          | 50      | -      | 50          | AD       | LL        | 67        | 5-7.2                 | Europe               |
|               |                      |          |    |   | measurement method     |          |         |        |             |          | LL        | 1         | 5-7.3                 | Europe               |

**Note.** SR denotes no. of systematic reviews identified, ‘adj’ denotes age-adjusted (baseline age is not relevant to measures of self-reported educational attainment), ‘ML’ denotes midlife (baseline age < 65), ‘LL’ denotes late-life (baseline age 65+), ‘?’ denotes unknown. ∧ is the percentage of primary studies where baseline age is not reported, and “Env.” is environmental. ‘Y’ denotes yes and ‘N’ denotes no. **Body of Evidence Metrics.** 1°N° denotes the quantity of evidence per risk factor; total number of primary studies for each risk factor 2Indicates standardization and variability of exposures measures within risk factors. 3The percentages of identified reviews which did or did not have specified clinical diagnosis as an inclusion criteria, or where this was not reported. 4Subtypes of dementia represented: AD, VaD, any. 5Ages groups represented, primary age group, and % of primary studies where age group is not reported. 6Geographical regions represented.
number of primary studies with lengths of follow-up in the following categories: <5 years, 5–9.9 years, 10–19.9 years, and 20+ years, or unknown length of follow-up was identified. The percentage of primary studies with long follow-up periods (i.e., ten or more years follow-up) was reported. Length of follow-up is important because dementia has a long prodromal period, so shorter studies have increased risk of reverse causality.

8. Geographical regions: global generalizability (see Table 1 and see Fig. 2), number of regions represented across all estimates in risk factor/total of six possible regions × 100. Risk of bias when generalizing findings in relation to a risk factor is increased if the majority of evidence is derived from a single geographical area.

**Meta-analysis quality**

A representativeness statistic was calculated using number of primary studies pooled per risk estimate divided by the total number of primary studies per risk factor. Lower scores indicate that the meta-analysis is reporting a smaller proportion of the available evidence base for that risk factor. It is expected that older meta-analyses would have a lower representativeness statistic and more recently published meta-analyses have a higher statistic (detailed summary on individual meta-analyses and pooled risk estimates in Supplementary Table 1). A validated measure of evidence overlap for meta-analyses termed Corrected Covered Area (CCA %) [12] was estimated for each risk factor and is reported in Supplementary Table 5, and associated interpretive descriptors are represented in Fig. 3.

**Publication quality**

Risk of bias of included reviews were rated using the AMSTAR scale [13] (Supplementary Table 3). AMSTAR provides rating of domains of potential bias and is not intended to be used as a total score. Studies included are listed in Supplementary Table 4.

**Data synthesis and analysis**

Data were collated and synthesized with a summary provided according to risk factor by age, i.e., exposure for midlife only, late-life only, or studies combining exposure in both. Results were also reported separately for AD, Any Dementia, and VaD where data were available. Summary effect sizes and 95% CI with fixed effects and random effects models for each meta-analysis were used to determine significance and size of study effects; between-study heterogeneity was assessed with I² (the proportion of between-study variance to the sum of within- and between-study variances), which ranges from 0% to 100%. Where meta-analyses contained non-prospective data or where I² was not reported, individual study HRs and 95% CI were extracted. Summary estimates and I² statistics were re-calculated using Meta-Analysis software version 3.0 and Stats Direct 3.1.

**RESULTS**

Of the 825 articles identified, 809 were screened and 203 reviewed at full-text of which 113 were deemed ineligible (reasons for exclusion provided in Supplementary Table 2). We identified 91 articles reporting meta-analyses that met criteria for our review (see Fig. 1), and these contained 271 pooled estimates for 36 risk factors for AD (Table 1), VaD, and Any Dementia (study characteristics are reported in Supplementary Table 1). Risk factors were classified as demographic, lifestyle (including diet and nutrient factors which were grouped together), medical, pharmacological, or environmental. BEMs are reported in Table 1 and Fig. 2 (for AD). The number of unique primary studies included in systematic reviews for a given risk factor ranged from two (e.g., carotid atherosclerosis, peripheral artery disease, antacids) to 90 (e.g., diets) (Fig. 2 and Supplementary Table 1) with more than 40 studies included for smoking, depression, and diabetes, and 20–39 studies included for education, alcohol, physical activity, body mass index (BMI), cholesterol,
hyper/hypotension, antihypertensives, and statins. CCA estimates indicated that degree of overlap between reviewed studies was highest for physical activity, diabetes, traumatic brain injury (TBI), cancer, stroke, statins, anti-inflammatories, hormone replacement therapy (HRT), and pesticides (Fig. 3). Risk factors with a high number of primary papers and frequency of reviews, but with slight to moderate CCA included: education, alcohol, diet, BMI, and atrial fibrillation. Fewer than five studies were identified for bilingualism, stress, carotid atherosclerosis, inflammatory markers, metabolic syndrome, peripheral artery disease, renal disease, serum uric acid, antacids, benzodiazepines, and pesticides. For around half of the risk factors, all the reviews included had been published in the last six years, in contrast to the risk factors of smoking, alcohol, and homocysteine where fewer than 40% of the reviews had been published within the past six years.

We found that individual meta-analyses did provide new and different information from each other. On average they reported a minority 27% of the total studies published per risk factor. This highlights the importance of considering the evidence per risk factor as a whole rather than relying on evidence from specific meta-analysis. In general, AMSTAR rating
quality was higher for more recent reviews (Supplementary Table 3). The most common area where studies lost points was lack of a specified “a priori” research design (e.g., registered protocol) (86% of reviews), and not providing a list of excluded studies (80% of reviews). It was assumed that protocols did not exist if not mentioned. Standard measures of exposures were lacking for cognitive engagement, diet, social engagement, stress, hormones, and pesticides, and risk factors varied greatly in the degree to which component meta-analyses used exposure measures consistently, e.g., meta-analyses of cognitive engagement included studies with exposure to high participation in cognitive activities, intellectual activities, and stimulating activities.

Around one quarter of the meta-analyses used standard outcome measures (Table 1). Reviews lacking a requisite clinical diagnosis criterion included dementia outcomes based on non-diagnostic measures like the Mini-Mental State Exam (MMSE), informant or self-report of medical history, or another non-standard cognitive test. Meta-analyses of BMI and smoking had particularly low proportions (<25%) of studies with specified clinical diagnostic criteria for dementia. Some meta-analyses (bilingualism, social engagement, sleep, anxiety, hearing loss, inflammatory markers, motor function, serum uric acid, antacids, and insulin sensitizers) did not report use of any standard outcomes or were unclear in their reporting. AD was the most common dementia subtype to be investigated as an outcome. Only 8/39 risk factors were evaluated for VaD. Social engagement, anxiety, hearing loss, and motor function have not been reviewed as risk factors for either VaD or AD.

Where age-group was reported, the evidence on bilingualism, cognitive and social engagement, atrial fibrillation, anxiety, cancer, carotid atherosclerosis, depression, hormones, inflammatory markers, metabolic syndrome, motor function, peripheral artery disease, renal disease, serum uric acid, stroke, HRT, and pesticides is drawn from studies that commenced in later life only (Table 1). In this case, it is unclear whether these factors, when occurring in midlife, are associated with dementia risk. Age group was not reported for antacids, benzodiazepines, and insulin sensitizers. The evidence for all other risk factors included studies of middle-aged as well as older adults, though there were specific gaps in age coverage for dementia sub-types; for example, most meta-analyses of risk factors for VaD only included exposures measured in late-life.

The greatest proportion of evidence from long follow-up (10+ years) was for motor function (80% of studies), insulin sensitizers (75% of studies), and bilingualism (75% of studies) (range 3–23 years but missing data precluded estimate of proportion with long follow-up). Additional risk factors with at least a third of the evidence derived from long follow-up included insulin sensitizers (75%), hearing-loss (70%), sleep (60%), BMI (57%), antacids and serum uric acid (50%), cancer (46%), diabetes (42%), cholesterol (41%), smoking (40%), education (33%), and HRT (30%) (see Fig. 3). In addition, 51% of risk factors identified had reviews with incomplete reporting of study follow-up duration with, on average, follow-up durations being omitted for 25% of component studies. Risk factors with the least complete follow-up information include anti-inflammatories (87% missing), benzodiazepines (100% missing), and TBI (81% missing). Risk factors for which the body of evidence is based only on short term follow-ups (<10 years) include carotid atherosclerosis, metabolic syndrome, peripheral artery disease, renal disease, serum uric acid, stroke, and pesticides. Those with the longest follow-up periods (40+ years) include smoking and BMI.

The most geographically representative evidence (covering five of six regions) was available for alcohol, physical activity, diabetes, motor function, and antihypertensives, followed by diet, smoking, social engagement, anxiety, hormones, and hyper/hypotension (four of six regions). Figure 2 shows the distribution of data on a map of the world with the most risk factor data drawn from Northern Europe.

There was no evidence from Asia/Middle East on bilingualism, cognitive engagement, stress, BMI, cancer, carotid atherosclerosis, inflammatory markers, metabolic syndrome, peripheral artery disease, antacids, benzodiazepines, anti-inflammatories, HRT, statins, and pesticides. Meta-analysis evidence from Australia/Oceana or Africa was relatively limited, and, with the exception diabetes, evidence from Latin America/Caribbean was unavailable.

Table 2 lists the 33 risk factors for AD for which meta-analyses were available, the number of studies contributing to each pooled risk estimate, the age of exposure (midlife or late-life), and the number of reviews contributing to results per risk factor. Egger’s test was non-significant for most risk factors and results for heterogeneity were varied both between meta-analysis of the same risk factor and between risk factors. Nineteen risk factors had effect
sizes drawn from more than five studies and had non-significant tests for bias or low to moderate heterogeneity ($I^2 < 50\%$).

Significant associations with AD increased risk were found for clinical depression versus no depression (RR: 2.04 (1.40, 2.98) [14]), diabetes versus no diabetes (RR: 1.39 (1.16, 1.66) [15] to 1.57 (1.41, 1.75) [16]), high BMI predominantly in midlife versus normal BMI (RR: 1.35 (1.19, 1.54) [17] to 2.04 (1.59, 2.69) [17]), low educational attainment versus high (RR: 1.32 (1.09, 1.59) [18] to 1.78 (1.43, 2.22) [19]), high homocysteine ((RR: 1.15 (1.09, 1.23) [20] to 2.50 (1.38, 4.56) [21]), smoking (RR: 1.12 (1.00, 1.26) [22] to 1.99 (1.33, 2.98) [23]), depression increase risk per increase in depressive symptom (RR: 1.06 (1.02, 1.10) [14] to 1.65 (1.42, 1.92) [24]), and decreased risk for NSAIDS (RR: 0.42 (0.26, 0.66) [25] to 0.74 (0.57, 0.97) [26]), alcohol (any or light/moderate versus abstinence) (RR: 0.43 (0.17, 0.69) [20] to 0.72 (0.61, 0.86) [27]), physical activity guidelines/more active versus inactive/less active (RR: 0.55 (0.36, 0.84) [28] to 0.80 (0.69, 0.94) [29]), fish (highest versus lowest) (RR: 0.64 (0.44, 0.92) [30] to 0.93 (0.90, 0.95) [31]), and coffee/caffeine intake versus no caffeine (RR: 0.69 (0.47, 0.90) [20] to 0.73 (0.55, 0.97) [32]). There was a mixed pattern of findings from meta-analyses of some risk factors, including statins, inflammatory markers, hyper/hypotension, and TBI. For the remaining risk factors (including cognitive activity, vitamin D deficiency, Mediterranean dietary pattern, stress, sleep, arthritis, carotid atherosclerosis, metabolic syndrome, serum uric acid), there was only one or a few systematic reviews and few contributing studies, thus providing insufficient evidence to draw even tentative conclusions (Table 2).

Figure 3 visually depicts the body of evidence metrics for all risk factors for all outcomes. The figure shows for example that for Bilingualism, data are recent, drawn from late-life with 10 years of exposure, based on 4 contributing studies in a single review, with most studies missing data on age of exposure. In comparison, the evidence for physical activity is drawn from 8 systematic reviews that include 35 cohort studies and include exposure in midlife and late-life. Data on diabetes is drawn from 8 reviews that include a total of 54 studies, and includes information on midlife and late-life. Hence the body of evidence for physical activity and diabetes is far larger and covers a wider age-range than the evidence for bilingualism.

Of the 26 risk factors evaluated with Any Dementia as an outcome (Supplementary Table 1), those for which there was at least one individual meta-analysis of more than 20 studies were physical activity, smoking, and depression. Among meta-analyses for education and atrial fibrillation, the largest number of studies was 14, for hearing loss, 13, for statins, 12, and for antioxidants, 11. In meta-analyses of alcohol, coffee, fat, fish, vitamin C, D, and E intake, sleep social engagement, anxiety, BMI, hormones, TBI, antihypertensives, insulin sensitizers, the largest number of studies included was 5–10. All other meta-analyses included at most 2–4 studies. High educational attainment (highest quartile compared with reference quartile) (RR: 0.59 (0.41, 0.87) [19]) was associated with a lower risk of Any Dementia. Late-life alcohol consumption (light to moderate and any, compared with abstinence) (RR: 0.65 (0.54, 0.79) [33] to 0.74 (0.61, 0.91) [27]), statins used in mid/late-life versus no statins (RR: 0.71 (0.61, 0.96) [34] to 0.87 (0.82, 0.92) [35]) higher levels of physical activity (as compared to lower levels) (RR: 0.72 (0.60, 0.86) [28] to 0.86 (0.76, 0.97) [36]), antihypertensives (RR: 0.79 (0.70, 0.89) [37] to 0.86 (0.75, 0.99) [38]) and antioxidants (RR: 0.87 (0.77, 0.98) [39]) and were associated with reduced risk of Any Dementia.

Cognitive engagement, Mediterranean diet, fish, fruit and vegetable, vitamin B and D, and tea drinking in mid- and late-life were associated with reduced risk but pooled estimates were derived from fewer studies (2–5 studies per estimate). Increased risk of Any Dementia was associated with insomnia (RR: 1.53 (1.07, 2.18) [40]) (5 studies with very high heterogeneity), shorter sleep duration as compared to longer sleep duration (RR: 1.42 (1.15, 1.77) [41]), low social engagement in late-life (RR: 1.41 (1.13, 1.75) [42] to 1.58 (1.19, 2.09) [42]) obesity (RR: 1.41 (1.20, 1.65) [43] to 1.91 (1.41, 2.62) [44]), underweight BMI in late-life (RR: 1.16 (1.07, 1.73) [45]), hearing loss (RR: 1.38 (1.23–1.53) [46]), low education (compared with higher levels of education) (RR: 1.32 (1.09, 1.59) [18] to 1.81 (1.59, 2.06) [19]), and smoking (RR: 1.13 (1.05, 1.22) [22] to 1.43 (1.15, 1.77) [39]). Coffee/caffeine was not associated with risk of Any Dementia.

Eight risk factors were evaluated for VaD (Supplementary Table 1), and meta-analyses for which there were eight or more studies included: diabetes (RR: 1.73 (1.61, 1.85) [47] to 2.49 (2.09, 2.97) [48]) and smoking (RR: 1.25 (1.05, 1.47) [22] to 1.78 (1.28, 2.47) [49]), with a single meta-analyses of six studies
Table 2
Summary of AD studies by risk factor

| Risk Factor         | Short reference | Exposure measure                  | Age group | RR          | I² (%) | Bias (Egger's p) | n   |
|---------------------|-----------------|-----------------------------------|-----------|-------------|--------|-----------------|-----|
| Demographics        |                 |                                    |           |             |        |                 |     |
| Education           | Xu 2016 [19]    | Lowest versus reference quartile  | adj       | 1.78 (1.43, 2.22) | 36.0   | absent          | 9   |
|                     | Xu 2015 [20]    | Low (<16 y) versus high (≥16 y)   | adj       | 1.60 (1.32–1.94)  | 57.0   | 0.00            | 14  |
|                     | Caamano-Isorna 2006 [18] | Lower versus highest levels     | adj       | 1.32 (1.09, 1.59) |        | absent          | 9   |
|                     | Xu 2016 [19]    | Highest versus reference quartile | adj       | 0.44 (0.32, 0.60) | 41.5   | 0.018           | 10  |
| Lifestyle           |                 |                                    |           |             |        |                 |     |
| Alcohol             | Anstey 2009 [27]| Drinker versus non-drinkers       | LL        | 0.66 (0.47, 0.94) | 0.0    | ~               | 2   |
|                     | Xu 2015 [20]    | Ever versus never                 | LL/?      | 0.43 (0.17, 0.69) | 0.0    | 0.33            | 3   |
|                     | Anstey 2009 [27]| Heavy/excessive versus non-drinker| LL        | 0.92 (0.59, 1.45) | 0.0    | 0.22            | 3   |
|                     | Xu 2015 [20]    | High versus low/none              | LL/?      | 0.96 (0.18, 1.74) | 78.8   | 0.56            | 3   |
|                     | Xu 2015 [20]    | Light-moderate consumption versus non-drinkers | LL/? | 0.61 (0.54, 0.68) | 0.0    | 0.44            | 5   |
|                     | Anstey 2009 [27]| Light to moderate versus non-drinkers| LL       | 0.72 (0.61, 0.86) | 56.4   | 0.36            | 6   |
| Cognitive engagement| Xu 2015 [20]    | High participation in cognitive activity | LL/? | 0.53 (0.42, 0.63) | 90.5   | 0.00            | 5   |
| Diet                | Singh 2014 [50] | Adherence to Mediterranean diet | LL       | 0.64 (0.46, 0.89) | 0.0    | ~               | 2   |
|                     | Xu 2015 [20]    | Caffeine/coffee drinking <1 cup coffee per day versus 1-2 cups | ML/? | 0.69 (0.47, 0.90) | 0.0    | 0.96            | 3   |
|                     | Wu 2016 [51]    | Fat, DHA                          | LL        | 0.71 (0.54, 0.94) | 0.0    | 0.98            | 3   |
|                     | Kim 2015 [52]   | Coffee intake-highest versus lowest | LL       | 0.71 (0.52, 0.97) | 0.0    | ~               | 3   |
|                     | Liu 2016 [32]   | Coffee intake-highest versus lowest | ML/LL  | 0.73 (0.55, 0.97) | 0.0    | 0.80            | 4   |
|                     | Barranco 2007 [53]| Coffee consumption versus non-consumption | ?  | 0.73 (0.54, 0.99) | 0.0    | ~               | 2   |
|                     | Xu 2015 [20]    | Fat, DHA/EPAnull versus lowest    | LL/?      | 0.76 (0.52, 1.11) | 68.3   | 0.04            | 4   |
|                     | Wu 2015 [30]    | Fat, DHA/EPAnull versus lowest    | LL        | 0.89 (0.74, 1.08) | 36.3   | 0.01            | 3   |
|                     | Xu 2015 [20]    | Fat, EPA                          | ?         | 0.96 (0.75, 1.16) | 0.0    | 0.25            | 3   |
|                     | Zhang 2016 [31] | Fat, DHA-0.1-g/d increment        | ML/LL     | 0.63 (0.51, 0.76) | 94.6   | 0.10            | 3   |
|                     | Zhang 2016 [31] | Fat, PUFA-8-g/d increment         | ML/LL     | 0.96 (0.65, 1.27) | 34.6%  | ~               | 2   |
|                     | Zhang 2016 [31] | Fat, EPA-0.1-g/d increment        | ML/LL     | 1.04 (0.85, 1.23) | 5.1    | 0.10            | 2   |
|                     | Wu 2015 [30]    | Fish intake-highest versus lowest | LL        | 0.64 (0.44, 0.92) | 59.0   | 0.10            | 6   |
|                     | Xu 2015 [20]    | Fish intake                       | LL/?      | 0.66 (0.43, 0.90) | 64.7%  | 0.54            | 6   |
|                     | Zhang 2016 [31] | Fish-increment of 1 serving/wk    | ML/LL     | 0.93 (0.90, 0.95) | 74.8%  | 0.174           | 5   |
|                     | Xu 2015 [20]    | Folate-high serum folate levels   | LL/?      | 0.51 (0.29, 0.73) | 16.0%  | 0.29            | 4   |
|                     | Kim 2015 [52]   | Tea intake-highest versus lowest  | LL        | 1.12 (0.83, 1.50) | 0.0%   | ~               | 3   |
|                     | Xu 2015 [20]    | Vitamin C intake                  | LL/?      | 0.74 (0.55, 0.93) | 0.0%   | 0.19            | 6   |
|                     | Xu 2015 [20]    | Vitamin E intake                  | LL/?      | 0.73 (0.62, 0.84) | 0.0%   | 0.81            | 6   |
|                     | Shen 2015 [54]  | Vitamin D deficiency (25(OH)D level <50 nmol/L) | LL/? | 1.21 (1.02, 1.41) | 0.0%   | ~               | 2   |

(Continued)
Table 2 (Continued)

| Risk Factor     | Short reference | Exposure measure                                                                 | Age group* | RR        | I² (%) | Bias (Egger’s p) | n  |
|-----------------|-----------------|----------------------------------------------------------------------------------|------------|-----------|--------|-----------------|----|
| Physical activity | Santos-Lozano 2016 [55] | Physically active (according to international PA guidelines; >150 min/week of MVPA) versus inactive | LL         | 0.60 (0.51, 0.71) | 5.6%   | 0.34            | 5  |
|                 | Xu 2015 [20]    | High participation in leisure-time PA                                             | LL/LL?     | 0.65 (0.46, 0.84) | 81.0%  | 0.09            | 10 |
|                 | Santos-Lozano 2016 [55] | Higher versus lower PA                                                            | ML/LL      | 0.65 (0.55, 0.75) | 39.3%  | 0.83            | 9  |
|                 | Daviglus 2011 [56] | Higher versus lower PA                                                            | ?          | 0.72 (0.53, 0.98) | –      | –              | 9  |
|                 | Xu 2017 [29]    | Higher versus lower PA                                                            | ML/LL      | 0.80 (0.69, 0.94) | 0.0%   | ~              | 8  |
| Sleep           | Bubu 2016 [58]  | All sleep problems/disorders listed in International Classification of Sleep Disorders versus none | ML/LL      | 1.47 (1.28, 1.69) | 66.9%  | 0.79            | 6  |
| Smoking         | Zhong 2015 [22] | Current versus never                                                              | LL         | 1.40 (1.13, 1.73) | 66.8%  | <0.01           | 12 |
|                 | Anstey 2007 [49] | Current versus former                                                             | LL/?       | 1.70 (1.25, 2.31) | 0.0%   | 0.70            | 4  |
|                 | Anstey 2007 [49] | Current versus never                                                              | LL/?       | 1.79 (1.43, 2.23) | 0.0%   | 0.89            | 4  |
|                 | Peters 2008 [59] | Current versus non-smokers                                                        | ML/LL/?    | 1.59 (1.15, 2.20) | 69.9%  | 0.19            | 8  |
|                 | Peters 2008 [59] | Current versus non-smokers                                                        | ?          | 1.99 (1.33, 2.98) | 56.5%  | ~              | 7  |
| Medical Arthritis | Xu 2015 [20]    | History of arthritis (self-report)                                               | LL/?       | 0.63 (0.42, 0.84) | 0.0%   | 0.83            | 2  |
| Atrial fibrillation | Kalantarian 2013 [60] | Yes versus no (ECG, medical history, ICD-9, unclear)                          | LL         | 1.47 (0.92, 2.34) | 68.2%  | ~              | 3  |
|                 | Xu 2015 [20]    | Yes versus no (medical records, self-report health questionnaire)                | LL         | 1.29 (0.97, 1.60) | 60.6%  | 0.94            | 3  |
| BMI             | Anstey 2011 [17] | Change (increase) continuous measures of BMI                                      | LL         | 0.72 (0.62, 0.84) | 71.5%  | ~              | 2  |
|                 | Xu 2015 [20]    | High BMI (>28/30) in midlife versus normal                                        | ML/LL/?    | 1.61 (1.11, 2.12) | 69.2%  | 0.11            | 6  |
|                 | Xu 2015 [20]    | High BMI (>25–30/abdominal obesity/BMI increase) in late-life                     | ML/LL      | 0.80 (0.64, 0.97) | 72.9%  | 0.95            | 12 |
|                 | Anstey 2011 [17] | Obese versus normal                                                              | ML/LL      | 2.04 (1.59, 2.69) | 82.8%  | ~              | 3  |
|                 | Loef 2013 [44]  | Obese versus normal                                                              | ML/LL      | 1.98 (1.24, 3.14) | –      | –              | 4  |
|                 | Meng 2014 [61]  | Obese versus normal                                                              | ML         | 1.88 (1.32, 2.69) | 59.1%  | 0.55            | 5  |
|                 | Beydoun 2008 [45] | Obese versus normal                                                              | ML/LL      | 1.80 (1.00, 3.29) | –      | <0.01           | 4  |
|                 | Anstey 2011 [17] | Obese versus not Obese                                                           | LL         | 1.46 (0.97, 2.21) | 42.3%  | ~              | 2  |
|                 | Anstey 2011 [17] | Overweight versus normal                                                          | ML/LL      | 1.35 (1.19, 1.54) | 92.0%  | ~              | 3  |
|                 | Loef 2013 [44]  | Overweight versus normal                                                          | ML/LL      | 1.44 (0.96, 2.15) | –      | –              | 4  |
|                 | Anstey 2011 [17] | Underweight versus normal                                                         | ML/LL      | 1.96 (1.32, 2.92) | 69.1%  | ~              | 3  |
| Risk Factor                | Short reference   | Exposure measure                                                                 | Age group* | RR      | $I^2$ (%) | Bias (Egger’s p) | n   |
|---------------------------|-------------------|----------------------------------------------------------------------------------|------------|---------|-----------|-----------------|-----|
| Cancer                    | Ma 2014 [62]      | History of cancer versus none (ICD code diagnosis)                               | LL         | 0.63    | 0.0%      | 0.28            | 5   |
|                           | Xu 2015 [20]      | Yes versus no (Questionnaire/self-report, ASL-M11 tumor registry)                | LL         | 0.65    | 6.7%      | 0.81            | 6   |
| Carotid atherosclerosis   | Xu 2015 [20]      | Yes versus no (carotid medina wall thickness)                                    | LL         | 1.65    | 31.1%     | ~               | 2   |
| Cholesterol               | Anstey 2017 [63]  | High cholesterol (>6.5 mmol/l) versus non-high-midlife                           | ML         | 2.14    | 12.9%     | ~               | 3   |
|                           | Meng 2014 [61]    | High cholesterol (>6.5 mmol/l) versus non-high-midlife                           | ML         | 1.72    | 8.5%      | possible^      | 4   |
|                           | Xu 2015 [20]      | Elevated serum total cholesterol level                                           | ML/LL      | 1.07    | 59.9%     | 0.02            | 16  |
|                           | Daviglus 2011     | Highest versus lowest quartile                                                    | ?          | 0.85    | -         | ~               | 3   |
|                           | Anstey 2017 [63]  | Highest versus lowest quartile-Tata cholesterol, late-life                       | LL         | 0.93    | 50.5%     | 0.28            | 4   |
|                           | Anstey 2017 [63]  | Low HDL-C                                                                          | LL         | 0.78    | 65.4%     | ~               | 3   |
|                           | Anstey 2008 [17]  | Second versus lowest quartile-Tata cholesterol, late-life                         | LL         | 0.85    | 40.1%     | ~               | 3   |
| Depression                | Cherbuin 2015     | Categorical clinical thresholds (>20/21 CES-D or equivalent)                      | LL         | 2.04    | 54.9%     | possible^      | 10  |
|                           | Diniz 2013 [24]   | Continuous (mostly CES-D & variants)                                             | ?          | 1.65    | 2.0%      | absent^         | 17  |
|                           | Xu 2015 [20]      | Continuous (self-reporting, CES-D, HAM, Questionaire, DSM-IV, Diagnosis, CAMDEX, Neuropsychiatric interview, SCL-90) | LL/?       | 1.08    | 40.3%     | 0.00            | 24  |
|                           | Cherbuin 2015     | Continuous symptomology measures-CES-D, HAM, GDS, SCL-90, the NEO                | LL         | 1.06    | 62.1%     | possible^      | 10  |
| Diabetes                  | Zhang 2017 [64]   | Any diabetes (Type I or II)                                                       | ?          | 1.53    | 18.5%     | absent^         | 17  |
|                           | Meng 2014 [61]    | Any diabetes (Type I or II)                                                       | ML/LL      | 1.40    | 10.6%     | –               | 4   |
|                           | Vagelatos 2013    | Type II diabetes, self-report and blood sampling                                 | ML/LL      | 1.57    | 38.7%     | 0.22            | 15  |
|                           | Gudala 2013 [65]  | Type II diabetes (self-reported, registry-based/antidiabetics use)               | ML/LL      | 1.56    | 9.8%      | 0.93            | 20  |
|                           | Cheng 2012 [48]   | Type II diabetes (according to standard criteria)                                | ML/LL      | 1.54    | 71.7%     | <0.01           | 18  |
|                           | Lu 2009 [15]      | Type II diabetes (medical history, laboratory test, antidiabetic medications)    | LL         | 1.39    | 0.0%      | <0.01           | 8   |
|                           | Xu 2015 [20]      | Type II diabetes (self-report, family report)                                    | ML/LL      | 1.33    | 70.4%     | 0.06            | 22  |
| Homocysteine              | Vagelatos 2013    | Type II diabetes, self-report and blood sampling                                 | ML/LL      | 1.57    | 38.7%     | 0.22            | 15  |
|                           | Van Dam 2009      | Hyperhomocysteinema                                                               | LL         | 2.50    | 81.6%     | ~               | 3   |
|                           | Xu 2015 [20]      | High total homocystein levels                                                     | ML/LL?     | 1.15    | 45.0%     | 0.00            | 8   |

(Continued)
| Risk Factor               | Short reference | Exposure measure                                      | Age group* | RR      | I² (%) | Bias (Egger’s p) | n  |
|--------------------------|-----------------|------------------------------------------------------|------------|---------|--------|-----------------|----|
| **Hormones**             |                 |                                                      |            |         |        |                 |    |
|                          | Wang 2016 [66]  | High versus normal levels of thyrotropin             | LL         | 1.70 (1.18, 2.45) | 42.2%  | 0.75            | 2  |
|                          | Wang 2016 [66]  | Low versus normal levels of thyrotropin              | LL         | 1.69 (1.31, 2.19) | 38.0%  | 0.74            | 4  |
|                          | Lv 2016 [67]    | Low plasma testosterone (in elderly men)             | ?          | 1.48 (1.12, 1.96) | 47.2%  | 0.15            | 7  |
|                          | Wang 2016 [66]  | Per SD increment in thyrotropin levels               | LL         | 0.89 (0.78, 1.01) | 31.3%  | 0.01            | 6  |
| **Hyper/Hypotension**    | Meng 2014 [61]  | All combined-high SBP, DBP, hypertension             | ML/LL      | 1.31 (1.01, 1.70) | 45.7%  | –               | 5  |
|                          | Meng 2014 [61]  | High DBP                                             | ML/LL      | 2.38 (1.34, 4.23) | 0.0%   | –               | 3  |
|                          | Meng 2014 [61]  | High SBP                                             | ML/LL      | 1.77 (0.93, 3.37) | 0.0%   | –               | 3  |
|                          | Xu 2015 [20]    | Higher SBP                                           | ?          | 1.02 (0.92, 1.13) | 68.7%  | <0.01           | 28 |
|                          | Meng 2014 [61]  | Hypertension versus none                             | ML/LL      | 1.10 (0.88, 1.37) | 48.6%  | –               | 2  |
|                          | Guan 2011 [65]  | Hypertension versus none                             | ML/LL      | 1.01 (0.87, 1.18) | 37.2%  | –               | 9  |
|                          | Xu 2015 [20]    | Lower DBP                                            | LL/?       | 1.14 (0.89, 1.39) | 60.0%  | <0.01           | 6  |
|                          | Power 2011 [68] | Per 10 mmHg DBP                                      | ML         | 0.93 (0.84, 1.04) | 12.4%  | 0.85            | 4  |
|                          | Power 2011 [68] | Per 10 mmHg DBP                                      | LL         | 0.94 (0.85, 1.04) | 14.0%  | 0.45            | 5  |
|                          | Power 2011 [68] | Per 10 mmHg increment SBP                            | ML         | 0.95 (0.90, 1.00) | 69.4%  | ~               | 4  |
|                          | Power 2011 [68] | Per 10 mmHg increment DBP                            | LL         | 0.95 (0.91, 1.00) | 0.0%   | 0.54            | 5  |
|                          | Sharp 2011 [69] | History of/current hypotension                        | ?          | 1.59 (1.29, 1.95) | 37.4%  | <0.01           | 6  |
| **Inflammatory markers** | Power 2011 [68] | History of hypertension                              | ML/LL      | 0.98 (0.80, 1.19) | 41.8%  | 0.69            | 12 |
|                          | Koyama 2013 [70]| C-reactive protein                                    | LL         | 1.36 (1.13, 1.63) | 40.3%  | ~               | 3  |
|                          | Koyama 2013 [70]| Interleukin-6                                         | LL         | 1.15 (0.84, 1.59) | 0.0%   | ~               | 4  |
|                          | Xu 2015 [20]    | NCEP ATP III criteria                                 | LL/?       | 0.71 (0.49, 0.93) | 36.5%  | 0.30            | 4  |
| **Metabolic syndrome**   | Xu 2015 [20]    | Ankle to Brachial Index < 0.9–11                      | LL/?       | 1.68 (0.97, 2.38) | 0.0%   | 0.51            | 2  |
|                          | Xu 2015 [20]    | eGFR (MDRD), I/Scr, questionnaire                     | LL/?       | 1.13 (0.68, 1.59) | 0.0%   | 0.67            | 3  |
| **Peripheral artery disease** | Xu 2015 [20] | Serum uric acid levels                               | ?          | 0.66 (0.52, 0.85) | 6.0%   | low risk^       | 3  |
|                          | Xu 2015 [20]    | Self-reported history of stroke                      | LL/?       | 0.97 (0.71, 1.24) | 40.9%  | 0.03            | 9  |
|                          | Zhou 2015 [72]  | Stroke diagnosis based on the International Classification of Diseases | LL | 1.59 (1.25, 2.02) | 0.0%   | ~               | 5  |
| **Renal Disease**        | Xu 2015 [20]    | Head trauma with/without loss of consciousness       | LL/?       | 1.18 (0.89, 1.47) | 7.5%   | 0.16            | 6  |
|                          | Li 2017 [73]    | Prior TBI                                            | LL/?       | 1.24 (1.04, 1.49) | 26.8%  | 0.32            | 8  |
|                          | Perry 2016 [74]| Prior TBI                                            | ?          | 0.95 (0.58, 1.54) | 51.4%  | 0.83            | 7  |
| **Pharmacological Antacids** | Virk 2015 [75] | Aluminum containing antacids                         | ?          | 0.70 (0.30, 1.80) | 0.0%   | ns              | 2  |
|                          | Virk 2015 [75]  | Antacid                                              | ?          | 0.83 (0.39, 1.78) | 0.0%   | ns              | 2  |
|                          | Xu 2015 [20]    | Anti-hypertensives                                    | LL/?       | 0.71 (0.59, 0.83) | 52.7%  | 0.36            | 5  |
|                          | Xu 2017 [38]    | Anti-hypertensives                                    | LL         | 0.83 (0.64, 1.07) | 40.5%  | possible^       | 6  |
|                          | Chang-Quan 2011 [76] | Anti-hypertensives                                  | ML/LL/?   | 0.92 (0.79, 1.08) | 0.0%   | 0.66            | 5  |
| **Anti-inflammatories**  | Guan 2011 [77]  | Anti-hypertensives                                    | ML/LL      | 0.92 (0.79, 1.08) | 0.0%   | 0.66            | 5  |
|                          | Wang 2015 [78]  | Aspirin                                              | LL/?       | 0.74 (0.57, 0.97) | 67.9%  | –               | 8  |
|                          | Etminan 2003 [79]| Aspirin                                              | ML/LL      | 0.85 (0.71, 1.03) | 80.5%  | 0.90            | 5  |
|                          | Wang 2015 [78]  | Non-aspirin NSAIDs                                   | LL/?       | 0.61 (0.43, 0.88) | 68.6%  | 0.04            | 7  |
|                          | Szekely 2004 [25]| NSAIDs-exposure for 2 or more years                | ML/LL/?   | 0.42 (0.26, 0.66) | 0.0%   | ~               | 3  |
|                          | Xu 2015 [20]    | NSAIDs                                               | LL/?       | 0.67 (0.44, 0.90) | 65.8%  | <0.01           | 9  |

(Continued)
Table 2
(Continued)

| Risk Factor          | Short reference | Exposure measure          | Age group* | RR   | I² (%) | Bias (Egger’s p) | n  |
|----------------------|-----------------|---------------------------|------------|------|--------|-----------------|----|
| NSAIDs-lifetime exposure | Szekely 2004 [25] | ML/LL/?                   | 0.74 (0.62, 0.89) | –    | absent | –               | 4  |
| All NSAIDs           | Wang 2015 [78]  | ML/?                      | 0.69 (0.56, 0.86) | 79.7%| 0.10   |                  | 12 |
| All NSAIDs           | Etminan 2003 [79]| ML/LL                     | 0.84 (0.54, 1.05) | 62.3%| 0.05   |                  | 6  |
| Any use versus never use | LeBlanc 2001 [80] | LL/ ?                    | 0.50 (0.30, 0.80) | 0.0% | 0.10   |                  | 2  |
| Any use versus never use | Xu 2015 [20]   | LL/?                      | 0.61 (0.46, 0.76) | 38.1 | <0.01  |                  | 4  |
| Any use versus never use | O’Brien 2014 [81]| ?/ ?                     | 0.69 (0.48, 1.00) | 31.4%| 0.78   |                  | 8  |
| Insulin-sensitizers versus non-insulin sensitizers | Ye 2016 [82] | ?/ ?                      | 0.90 (0.55, 1.45) | –    | unobvious |                  | 2  |
| HRT                  | Zhou 2007 [83]  | Any use versus non-user   | ?/ ?       | 0.90 (0.65, 1.25) | 0.0% | 0.0% | 3  |
| Current use versus never use | Xu 2015 [20]  | LL/ ?                    | 0.59 (0.45, 0.73) | 26.4%| 0.29   |                  | 5  |
| Former use versus never use | Xu 2015 [20]  | ?/ ?                      | 1.28 (0.69, 3.24) | 74.6%| ~      |                  | 2  |
| Longer use versus never use | Xu 2015 [20]  | ?/ ?                      | 0.24 (0.07, 0.70) | 0.0% | ~      |                  | 2  |
| Users versus non-users | Wong 2013 [84] | ?/ ?                      | 0.70 (0.60, 0.80) | 18.2%| minimal |                  | 2  |
| Users versus non-users | Richardson 2013 [35] | ML/LL/?         | 0.79 (0.63, 0.99) | 91.6%| 0.38   |                  | 10 |
| Environmental Pesticides | Yan 2016 [85]  | Pesticide exposure        | LL/ ?      | 1.37 (1.08, 1.75) | 0.0% | 0.66 | 3  |
| Occupational exposure to pesticides | Xu 2015 [20] | LL/ ?                    | 1.26 (0.93, 1.59) | 5.4% | 0.78   |                  | 3  |

Note.*the primary age represented per pooled effect (RR) is denoted by bold text. ‘adj’ denotes age-adjusted (baseline age is not relevant to measures of self-reported educational attainment), ‘ML’ denotes midlife (baseline age < 65), ‘LL late-life (baseline age 65+) and ‘?’ unknown. ‘RR’ denotes risk ratio, which is the pooled effect size. ‘¬’ denotes not reported. ‘~’ indicates there were too few primary studies to calculate Egger’s p. ▲ bias as indicated by visual inspection of funnel plot. Egger’s values are as reported in primary reviews, but not a recommended measure of bias when for n < 10. ‘n’ is the number of primary studies included in the meta-analysis for each RR.

Identified for hypo/hypertension. Late-life smoking and overweight/obese BMI in mid- and late-life were consistently associated with increased risk of VaD. Reduced risk was associated with light to moderate alcohol consumption (compared to abstinence) and physical activity. All other meta-analyses included 2–4 primary studies.

Overall heterogeneity of studies within reviews was variable and notably high for the one meta-analysis of cognitive engagement and AD (I² = 90.5%) and for the range of meta-analyses for diet.

DISCUSSION

Increased risk for either or all of AD, VaD, or Any Dementia is associated with low education, diabetes, smoking, depression, midlife obesity, high homocysteine, hypertension (VaD only), atrial fibrillation (Any Dementia only), and social engagement (Any Dementia only). The data for social engagement were limited to late-life and included varied measures. We also found that reduced risk was consistently associated with physical activity, fish consumption, light alcohol consumption, antihypertensives (Any Dementia only), and statin use (AD and Any Dementia). Hearing loss was associated with increased risk of Any Dementia but there has been no review of hearing loss in relation to AD or VaD [4], and relatively limited evidence is available for cognitive engagement, dietary pattern, and specific nutrients as protective factors. Note this reflects the limited evidence available for these risk factors currently and it is not a statement about their putative effect.

The gaps in the evidence base on risk factors for dementia are remarkable. By far the majority of data are reported for AD. Data are limited on vascular risk factors for VaD, with only one meta-analysis on physical activity, and no meta-analysis on statins in relation to VaD. A significant number of risk factors have been established primarily in studies of older adults (alcohol, atrial fibrillation, social engagement, cognitive engagement, depression, hormones, metabolic syndrome, peripheral artery disease, renal disease, serum uric acid, stroke, pesticides) thus omitting midlife exposure (which leads to gaps in long term follow-up). Major gaps occur in data from non-European and non-North-American continents. For example, data on BMI are drawn from fewer than 40% of world regions and there are no meta-analysis data in this review on BMI as a risk factor for dementia from Asian samples. Evidence for stress, inflamma-
Fig. 3. (Continued)
tory markers, and peripheral artery disease is drawn from one region. Sleep and social engagement as risk factors have not been reviewed in relation to dementia subtypes. Although the AMSTAR scores were generally high, we identified a lack of commonly used exposure measures for some risk factors (e.g., cognitive engagement). The AMSTAR rating does not capture some important methodological features that contribute to quality and bias in relation to this specific field and we needed to develop new metrics to capture important causes of bias in this literature.

The strengths of this review include its comprehensiveness and the evaluation of study quality and quantity. Reviews had clinical diagnoses of dementia and exclusion of individuals with dementia at baseline. This review has not considered mediating factors or whether risk factors are proxies for other variables. For example, it is possible that the risk of dementia associated with BMI is mediated by cultural or genetic factors such as Western-style diet and that BMI is a proxy for other socio-cultural factors. It is also possible that genotype interacts with risk exposure such that subgroups of the population may benefit more from risk reducing strategies or be harmed more by specific exposures (e.g., alcohol drinking). In addition, reverse causality was not evaluated and is a particular concern for risk factors identified only in late-life data such as cognitive engagement and AD. Meta-analyses do not include all published studies so the review may not include all the available data on every risk factor reviewed. Another potential source of bias is that selected meta-analyses may over-represent older primary studies which may not be relevant to current cohorts.

Understanding the risk and protective factors influencing cognitive aging and dementia requires a life-course approach and studies with long-term follow-ups. Much work is needed to identify critical time points for exposure, and to establish whether a common set of risk factors applies in different countries, at different ages of exposure, and for different dementia subtypes. Given the overlap of risk factors for dementia with other chronic disease areas, it is economical to adopt global chronic disease strategies for key risk factors such as smoking, insufficient physical activity, diabetes, depression, and hypertension. However, as evidence grows we expect more nuanced approaches to dementia risk reduction will be needed for specific populations and age-groups. The evidence reported in this review may be used to inform guideline development and identify research gaps, and areas where policy is based on strong versus weak evidence. This review provides the best evidence currently available representativeness, quality and quantity of evidence on risk factors for dementia.

ACKNOWLEDGMENTS

NHMRC Fellowship 1102694 to KJA, NHMRC Dementia Centre for Research Collaboration, NHMRC CRE1100579 to KJA; NeuRA Discovery Grant to KJA.
Authors’ disclosures available online (https://www.j-alz.com/manuscript-disclosures/19-0181r2).

SUPPLEMENTARY MATERIAL

The supplementary material is available in the electronic version of this article: http://dx.doi.org/10.3233/JAD-190181.

REFERENCES

[1] Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (2006) Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. *Lancet* 367, 1747-1757.

[2] Brookmeyer R, Kawas CH, Abdallah N, Paganini-Hill A, Kim RC, Corrada MM (2016) Impact of interventions to reduce Alzheimer’s disease pathology on the prevalence of dementia in the oldest-old. *Alzheimers Dement* 12, 225-232.

[3] Leshner AL, Landis S, Stroud C, Downey A (2017) *Preventing cognitive decline and dementia: A way forward*. National Academies of Sciences, Engineering, and Medicine: Health and Medicine Division National Academies Press, Washington, DC.

[4] Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J (2017) Dementia prevention, intervention, and care. *Lancet* 390, 2673-2734.

[5] Williams JW, Plassman BL, Burke J, Holsinger T, Benjamin S (2010) *Preventing Alzheimer’s Disease and Cognitive Decline*. Evidence Report/Technology Assessment No. 193. (Prepared by the Duke Evidence-based Practice Center under Contract No. HHS A290-2007-10066-I.) AHRQ Publication No. 10-E005. Agency for Healthcare Research and Quality, Rockville, MD.

[6] National Collaborating Centre for Mental Health (2016) A *NICE–SCIE Guideline on supporting people with dementia and their carers in health and social care - Revised*. National Clinical Practice Guideline British Psychological Society and Gaskell, United Kingdom.

[7] Ioannidis J (2017) Next-generation systematic reviews: Prospective meta-analysis, individual-level data, networks and umbrella reviews. *Br J Sports Med* 51, 1456-1458.

[8] Chen Y, Yang K, Marušič A, Qaseem A, Meerpohl JJ, Florshutz J (2015) Summarizing systematic reviews: Methodological development, conduct and reporting of an umbrella review approach. *Int J Evid Based Healthc* 13, 132-140.

[9] Roman GC, Tatemichi TK, Erkinjuntti T, Cummings J, Masdeu J, Garcia Ja, Amaducci L, Ongogojo J-M, Brun A, Hofman A (1993) Vascular dementia diagnostic criteria for research studies: Report of the NINDS-AIREN International Workshop. *Neurology* 43, 250-250.

[10] Pieper D, Antoine S-L, Mathes T, Neugebauer EA, Eikermann M (2014) Systematic review finds overlapping reviews were not mentioned in every other overview. *J Clin Epidemiol* 67, 368-375.
